| Autor: |
CAO Xiaoshan, CONG Binbin |
| Jazyk: |
English<br />Chinese |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Zhongguo aizheng zazhi, Vol 33, Iss 3, Pp 288-292 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1007-3639 |
| DOI: |
10.19401/j.cnki.1007-3639.2023.03.013 |
| Popis: |
Triple-positive breast cancer (TPBC) refers to breast cancer with positive expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), accounting for 5%-10% of all pathological types of breast cancer. TPBC is a special subtype of Luminal B breast cancer, which can receive both endocrine therapy and targeted therapy. TPBC is a special subtype of Luminal B breast cancer, which can receive both endocrine therapy and targeted therapy. The current guidelines recommend that anti-HER2-targeted therapy combined with chemotherapy is the first choice for TPBC treatment. However, the pathological complete response rate of TPBC is lower than that of hormone receptor negative/HER2-positive breast cancer. Moreover, patients with estrogen receptor expression >30% benefit less from anti-HER2-targeted therapy combined with chemotherapy. With the advent of various anti-HER2 targeted drugs and the clinical application of cyclin-dependent kinase 4 and 6 inhibitors, the combination of targeted therapy and endocrine therapy becomes possible for highly selected patients. This article reviewed the research progress of TPBC endocrine therapy combined with targeted therapy. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
